The second class of anti-influenza agents authorized for clinical therapy is represented by the NA inhibitors (NAIs), able to prevent the cellular sialic acid (SA) cleavage by viral NA, which is fundamental for the efficient detachment and release of the newly synthesized virions from the infected host cell (Fig. 1). This evidence concerns the gene XK and influenza.